Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2006-04-12
2010-06-29
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
Reexamination Certificate
active
07745494
ABSTRACT:
The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.
REFERENCES:
patent: 4294852 (1981-10-01), Wildnauer et al.
patent: 4374775 (1983-02-01), Dotz et al.
patent: 4719239 (1988-01-01), Muller et al.
patent: 4840970 (1989-06-01), Ohasi et al.
patent: 4906411 (1990-03-01), Shinnaka et al.
patent: 4966779 (1990-10-01), Kirk
patent: 5134127 (1992-07-01), Stella et al.
patent: 5155031 (1992-10-01), Posner et al.
patent: 5180747 (1993-01-01), Matsuda et al.
patent: 5356636 (1994-10-01), Schneider et al.
patent: 5376645 (1994-12-01), Stella et al.
patent: 5412125 (1995-05-01), Philippe et al.
patent: 5510391 (1996-04-01), Elson
patent: 5637741 (1997-06-01), Matsumoto et al.
patent: 5643583 (1997-07-01), Voultoury et al.
patent: 5650156 (1997-07-01), Grinstaff et al.
patent: 5770774 (1998-06-01), Joo et al.
patent: 5785976 (1998-07-01), Westesen et al.
patent: 5885486 (1999-03-01), Westesen et al.
patent: 5916749 (1999-06-01), Bandman et al.
patent: 6013665 (2000-01-01), DeMichele et al.
patent: 6110891 (2000-08-01), Pusztai et al.
patent: 6160007 (2000-12-01), DeMichele et al.
patent: 6187822 (2001-02-01), Leibovich
patent: 6207176 (2001-03-01), Howard et al.
patent: 6264986 (2001-07-01), Hahnlein et al.
patent: 6383471 (2002-05-01), Chen et al.
patent: 6426078 (2002-07-01), Bauer et al.
patent: 6428949 (2002-08-01), Bandman et al.
patent: 6524594 (2003-02-01), Santora et al.
patent: 6537579 (2003-03-01), Desai et al.
patent: 6576660 (2003-06-01), Liao et al.
patent: 6579994 (2003-06-01), Sankarasubbier et al.
patent: 6582710 (2003-06-01), Deckers et al.
patent: 6596287 (2003-07-01), Deckers et al.
patent: 6599513 (2003-07-01), Deckers et al.
patent: 6660306 (2003-12-01), Peshoff
patent: 6696484 (2004-02-01), Liao et al.
patent: 6774100 (2004-08-01), Vishnupad
patent: 6780439 (2004-08-01), Wilk
patent: 6979454 (2005-12-01), Lindahl et al.
patent: 7094431 (2006-08-01), Peshoff
patent: 7326690 (2008-02-01), Henry et al.
patent: 7402557 (2008-07-01), Miller et al.
patent: 7405188 (2008-07-01), Chen
patent: 2002/0061304 (2002-05-01), Miller et al.
patent: 2003/0139353 (2003-07-01), Jackson et al.
patent: 2003/0170187 (2003-09-01), Marchal
patent: 2004/0040011 (2004-02-01), Bosworth et al.
patent: 2004/0047852 (2004-03-01), Kennedy
patent: 2004/0062817 (2004-04-01), Peshoff
patent: 2004/0081674 (2004-04-01), Franke
patent: 2004/0138218 (2004-07-01), Pallen et al.
patent: 2004/0265396 (2004-12-01), Peshoff
patent: 2005/0048008 (2005-03-01), Gupta
patent: 2005/0092969 (2005-05-01), Ueda et al.
patent: 2005/0118187 (2005-06-01), Yu
patent: 2005/0148521 (2005-07-01), Ben-Sasson et al.
patent: 2006/0002439 (2006-01-01), Lee
patent: 2006/0058398 (2006-03-01), Kamei et al.
patent: 2006/0216342 (2006-09-01), Torchilin et al.
patent: 2006/0275504 (2006-12-01), Chen
patent: 2007/0025950 (2007-02-01), Elson
patent: 2007/0142462 (2007-06-01), Kennedy
patent: 2007/0238697 (2007-10-01), Jackson et al.
patent: 3514724 (1986-10-01), None
patent: 0392845 (1990-10-01), None
patent: 1214930 (2002-06-01), None
patent: 2005-206521 (2005-08-01), None
patent: WO-94/23023 (1994-10-01), None
patent: WO-97/39746 (1997-10-01), None
patent: WO-01/64214 (2001-09-01), None
patent: WO-01/91740 (2001-12-01), None
patent: WO-02/13780 (2002-02-01), None
patent: WO-02/20525 (2002-03-01), None
patent: WO-02/47642 (2002-06-01), None
patent: WO-03/018033 (2003-03-01), None
patent: WO-03/061566 (2003-07-01), None
patent: WO-03/101415 (2003-12-01), None
patent: WO-2004/019923 (2004-03-01), None
patent: WO-2005/032523 (2005-04-01), None
patent: WO-2006/029893 (2006-03-01), None
patent: WO-2006/056889 (2006-06-01), None
patent: WO-2006/107827 (2006-10-01), None
patent: WO-2007/147128 (2007-12-01), None
patent: WO-2008/004231 (2008-01-01), None
The HER1/EGFR-Inhibitor Rash Management Forum in New York City, Jan. 2004 (as evidenced by Perez-Soler et al (The Oncologist 10:345-356, 2005)).
Abdelmohsen et al (J Biol Chem 278:38360-38367, 2003).
Baselga et al (J Clin Oncol 20:4292-4302, 2002).
Bae, Eun Young et al., “A New VHR Dual-Specificity Protein Tyrosine Phosphatase Inhibitor fromDendrobium moniliforme,” Planta Med., vol. 70:869-870 (2004).
Cohen, Ezra E.W. et al., “Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,”Journal of Clinical Oncology, vol. 21(10):1980-1987 (2003).
Gerling, Norbert et al., “The tyrosine phosphatase inhibitor orthovanadate mimics NGF-induced neuroprotective signaling in rat hippocampal neurons,”Neurochemistry International, vol. 44:505-520 (2004).
Lage, Augustin et al., “Targeting epidermal growth factor receptor signaling: early results and future trends in oncology,”Annals of Medicine, vol. 35(5):327-336 (2003).
Lee, Kyeong et al., “CD45 Protein-Tyrosine Phosphatase Inhibitor Development,”Current Topics in Medicinal Chemistry, vol. 3:797-807 (2003).
Liem, David A. et al., “The Tyrosine Phosphatase Inhibitor Bis(Maltolato)-Oxovanadium Attenuates Myocardial Reperfusion Injury by Opening ATP-Sensitive Potassium Channels,”The Journal of Pharmacology and Experimental Therapeutics, vol. 309(3):1256-1262 (2004).
LoRusso, Patricia M., “Phase I Studies of ZD1839 in Patients With Common Solid Tumors,”Seminars in Oncology, vol. 30(1, Suppl. 1):21-29 (2003).
Lou, Wendy W. et al., “Effects of Topical Vitamin K and Retinol on Laser-Induced Purpura on Nonlesional Skin,”Dermatol. Surg., vol. 25:942-944 (1999).
Matschiner, John T. et al., “Metabolism and Vitamin K Activity ofcisPhylloquinone in Rats,”J. Nutrition, vol. 102:625-630 (1972).
Page, R.C. et al., “Dermatitis from Topical Application of 2-Methyl-1:4-Naphthoqunone (Synthetic Vitamin K Analogue),”The American Journal of the Medical Sciences, vol. 203:566-569 (1942).
Sah, Peter P.T., “Synthesis of 3-Methyl-4-Amino-1-naphthol hydrochloride (vitamin K) and related vitamin-K-active compounds,”Zeitschrift für Vitamin-, Hormon- und Fermentforschung, vol. 3(3-4):324-345 (1949-1950).
Shah, Neha S. et al., “The effects of topical vitamin K on bruising after laser treatment,”J. Am. Acad. Dermatol., vol. 47:241-244 (2002).
Ulbrich, A.P., “Topical application of menadione, a synthetic vitamin K: Preliminary report,”J. Am. Osteopathic Assoc., vol. 60:370-374 (1961).
Vanhoefer, Udo et al., “Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor,”J. Clin. Oncol., vol. 22:175-184 (2004).
Abdelmohsen, Kotb et al., “Epidermal Growth Factor Receptor Is a Common Mediator of Quinone-induced Signaling Leading to Phosphorylation of Connexin-43,”The Journal of Biological Chemistry, vol. 278(40):38360-38367 (2003).
Bernier, J. et al., “Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck,”Annals of Oncology, vol. 19(1):142-149 (2007).
Busam, K.J. et al., “Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225,”British Journal of Dermatology, vol. 144:1169-1176 (2001).
deBeer, Edwin J. et al., “Routes of Administration of Materials Capable of Acting as Vitamin K,”Proc. Soc. Exp. Biol and Med., vol. 46:535-537 (1941).
Elson, Melvin L., “Topical Phytonadione (Vitamin K1) in the Treatment of Actinic and Traumatic Purpura,”Cosmetic Dermatology, vol. 8(12):25-27 (1995).
Russell, H.K. et al., “Effect of Topical Application of 2-Methyl-1,4-Naph-Thoquinone (Synthetic Vitamin K Analogue) on the Prothrombin Level of Newborn Infants. With Refe
Ling Yi-He
Perez-Soler Roman
Albert Einstein College of Medicine of Yeshiva University
Fetterolf Brandon J
Kanik Cynthia L.
Lahive & Cockfield LLP
Remillard Jane E.
LandOfFree
Vitamin K for prevention and treatment of skin rash... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vitamin K for prevention and treatment of skin rash..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vitamin K for prevention and treatment of skin rash... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4181538